DNA-damaging modalities as treatment for cancers have been now been there for several decades. Despite it being able to kill cancer cells, issues with relation to second cancers, resistance and recurrence of cancers and non-specificity related adverse effects have limited their application and the advance in the field that was anticipated with their usage. My recent comprehensive review discusses these aspects and proposes the concept of existence of distinct thresholds of DNA-damage that maybe used to design better and more effective clinical strategies and trials in the future.
The LINKS to the paper :
http://cancerres.aacrjournals.org/content/early/2015/04/30/0008-5472.CAN-14-3247.abstract
https://www.researchgate.net/publication/275659825_DNA_Damage_in_Cancer_Therapeutics_A_Boon_or_a_Curse
The LINKS to the paper :
http://cancerres.aacrjournals.org/content/early/2015/04/30/0008-5472.CAN-14-3247.abstract
https://www.researchgate.net/publication/275659825_DNA_Damage_in_Cancer_Therapeutics_A_Boon_or_a_Curse
No comments:
Post a Comment